Caris Life Sciences applied to the New York State Department of Health for authorization of its Caris Assure blood-based testing. The company uses AI-driven precision medicine to analyze molecular profiles. This regulatory step expands its clinical reach into one of the strictest healthcare markets. Practitioners can expect broader access to these liquid biopsy tools.